Local generic drugmaker Mylan got a boost Tuesday from its largest shareholder in its effort to thwart a hostile takeover.

Abbott Laboratories, which owns a 14.5 percent stake in Mylan, said it plans to support Mylan’s bid to buy over-the-counter generic drug specialist Perrigo.

Abbott officials “believe Mylan’s standalone strategy and acquisition of Perrigo will further enhance its platform, is strategically compelling, value enhancing for shareholders and offers a clear path to completion,” Abbott CEO Miles White said in a statement.

Mylan, which is headquartered in the Netherlands but has its operations base in Cecil, has said it will hold a special meeting of Mylan shareholders early in the third quarter to seek approval for the Perrigo transaction, which Perrigo’s board has rejected. Mylan has not yet set a specific date for the meeting. If Mylan wins the shareholders’ OK, it plans to take its offer directly to Perrigo shareholders.

Advertise with us

“We are very pleased that, while Abbott is under no obligation to do so, Abbott has voluntarily chosen to express its support of Mylan,” executive chairman Robert Coury said in a statement.

Mylan’s pursuit of Dublin-based Perrigo is seen as a move to block an unsolicited acquisition by Israel’s Teva Pharmaceutical Industries. Teva has said it would drop its takeover effort if Mylan succeeds in buying Perrigo.

“There is a strong strategic and cultural fit in combining Teva and Mylan, and Teva remains fully committed to consummating a transaction that greatly benefits our respective stockholders, customers, patients and employees,” a Teva spokesperson said in an email Tuesday.

Abbott, based in Chicago, became Mylan’s biggest shareholder in February when Mylan bought a major chunk of Abbott’s generic operations outside of the United States.

Teva, which in recent weeks has been buying Mylan shares on the open market, is the company’s seventh-largest shareholder.

Advertise with us

Mylan shares rose $1.54, or 2.09 percent, Tuesday to close at $72.05, while Perrigo added $7.95, or 4.34 percent, to $191.25. Teva lost 28 cents, or .46 percent, to close at $60.40.

Patricia Sabatini: psabatini@post-gazette.com or 412-263-3066.